New Delhi, Aug 5:  

Jubilant Life Sciences has received final approval from the US health regulator for its Tizanidine Hydrochloride capsules used for the management of spasticity.

Jubilant Pharma Ltd has received Abbreviated New Drug Application (ANDA) final approval for Tizanidine Hydrochloride capsules in the strengths of 2 mg, 4 mg, and 6 mg, Jubilant Life Sciences said in a BSE filing today.

The product is a generic version of Acorda’s Zanaflex capsules. The capsules are used for the management of spasticity, Jubilant Life Sciences said.

Spasticity is a condition in which people can suffer severe, painful muscle spasms and/or rigidity during the day and night.

“This is the fifth approval that we have received from the USFDA during the current financial year”, it added.

As on June 30, 2017, the company had 84 ANDAs for oral solids filed in the US, of which 53 have been approved, Jubilant Life Sciences said.

(This article was published on August 5, 2017)
Post Comment

Get more of your favourite news delivered to your inbox

Please enter your email. Thank You.
Newsletter has been successfully subscribed.